The CAPP II trial of aspirin in Lynch syndrome/HNPCC: is it time for everyone to be treated?
- PMID: 33420651
- DOI: 10.1007/s10689-020-00215-z
The CAPP II trial of aspirin in Lynch syndrome/HNPCC: is it time for everyone to be treated?
References
-
- Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin JP et al (2020) Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet 395(10240):1855–1863 - DOI
-
- Burn J, Bishop DT, Mecklin JP, Macrae F, Moslein G, Olschwang S et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359(24):2567–2578 - DOI
-
- Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378(9809):2081–2087 - DOI
-
- Yurgelun MB, Chan AT (2020) Aspirin for Lynch syndrome: a legacy of prevention. Lancet 395(10240):1817–1818 - DOI
-
- Reyes-Uribe L, Wu W, Gelincik O, Bommi PV, Francisco-Cruz A, Solis LM et al (2020) Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut 69(10):1–12
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
